{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:13:50Z","timestamp":1772763230766,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T00:00:00Z","timestamp":1471392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Thar Pharmaceutical Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Markers of bone metabolism, such as N-telopeptide of type I collagen (NTX), have been demonstrated to be prognostic in previous trials of breast cancer (BC) patients with bone metastases (BMs). In the present study, we tested the survival effect of the NTX response to zoledronic acid (ZA) at 3 and 12 months in a contemporaneous cohort of BC patients with BMs and evaluated the influence of extraskeletal metastatic disease on NTX variation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>The present study was a prospective cohort study of consecutive BC patients diagnosed and treated at a single center. Patients presenting with de novo radiological evidence of BMs who started monthly intravenous ZA were included. Urinary NTX was measured at baseline and 1, 3, 6, 9, and 12 months after ZA introduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Overall, 71 patients were enrolled, 32 with BMs and 39 with BMs plus extraskeletal metastases. The proportion of patients with elevated NTX at baseline and 3 and 12 months was 49.3%, 26.6%, and 34.2%, respectively. The variables associated with survival included age at diagnosis, tumor estrogen receptor status, and NTX at 3 and 12 months. Multivariate analysis showed that, in addition to age at diagnosis, only the 3-month NTX level was significantly associated with survival. Patients with BMs plus extraskeletal metastases had an erratic NTX variation pattern, unrelated to survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>In the present contemporaneous cohort of BC patients with BMs, the NTX response at 3 months was strongly associated with survival. Furthermore, an early response to ZA was strongly associated with long-term NTX control. Finally, patients with BMs plus extraskeletal metastases had an erratic NTX variation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0527","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T02:03:35Z","timestamp":1471485815000},"page":"1418-1426","source":"Crossref","is-referenced-by-count":19,"title":["N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases"],"prefix":"10.1093","volume":"21","author":[{"given":"Arlindo R.","family":"Ferreira","sequence":"first","affiliation":[{"name":"Hospital de Santa Maria, Lisbon, Portugal"},{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}]},{"given":"Irina","family":"Alho","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}]},{"given":"Ning","family":"Shan","sequence":"additional","affiliation":[{"name":"Thar Pharmaceuticals Inc., Tampa, Florida, USA"}]},{"given":"Margarida","family":"Matias","sequence":"additional","affiliation":[{"name":"Hospital de Santa Maria, Lisbon, Portugal"}]},{"given":"Mariana","family":"Faria","sequence":"additional","affiliation":[{"name":"Hospital de Santa Maria, Lisbon, Portugal"}]},{"given":"Sandra","family":"Casimiro","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}]},{"given":"Kim","family":"Leitzel","sequence":"additional","affiliation":[{"name":"Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA"}]},{"given":"Suhail","family":"Ali","sequence":"additional","affiliation":[{"name":"Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[{"name":"Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA"}]},{"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[{"name":"Hospital de Santa Maria, Lisbon, Portugal"},{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2016,8,17]]},"reference":[{"key":"2021122309581400400_B1","first-page":"49","volume-title":"Bone Metastases","author":"Galasko","year":"1981"},{"key":"2021122309581400400_B2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"2021122309581400400_B3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"2021122309581400400_B4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"2021122309581400400_B5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bonekey.2015.35","article-title":"Bone remodeling markers and bone metastases: From cancer research to clinical implications","volume":"4","author":"Ferreira","year":"2015","journal-title":"Bonekey Rep"},{"key":"2021122309581400400_B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/ctrv.1999.0143","article-title":"Tumour progression and angiogenesis in bone metastasis from breast cancer: New approaches to an old problem","volume":"26","author":"Pluijm","year":"2000","journal-title":"Cancer Treat Rev"},{"issue":"suppl 3","key":"2021122309581400400_B7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN task force report: Bone health in cancer care","volume":"11","author":"Gralow","year":"2013","journal-title":"J Natl Compre Canc Netw"},{"key":"2021122309581400400_B8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3233\/BD-2010-0327","article-title":"Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?","volume":"33","author":"Lipton","year":"2011","journal-title":"Breast Dis"},{"key":"2021122309581400400_B9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bone.2009.11.016","article-title":"The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases","volume":"46","author":"Lester","year":"2010","journal-title":"Bone"},{"key":"2021122309581400400_B10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309581400400_B11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122309581400400_B12","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309581400400_B13","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309581400400_B14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"The Oncologist"},{"key":"2021122309581400400_B15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JOP.2011.000212","article-title":"American Society of Clinical Oncology clinical practice guideline update: Recommendations on the role of bone-modifying agents in metastatic breast cancer","volume":"7","author":"Van Poznak","year":"2011","journal-title":"J Oncol Pract"},{"issue":"suppl 3","key":"2021122309581400400_B16","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309581400400_B17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122309581400400_B18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"2021122309581400400_B19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"2021122309581400400_B20","first-page":"LBA9500a","article-title":"Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial","volume":"32","author":"Gabriel","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309581400400_B21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"2021122309581400400_B22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrclinonc.2011.64","article-title":"Clinical implications of cancer self-seeding","volume":"8","author":"Comen","year":"2011","journal-title":"Nat Rev Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/12\/1418\/41877461\/oncolo_21_12_1418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/12\/1418\/41877461\/oncolo_21_12_1418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:48:01Z","timestamp":1640321281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/12\/1418\/6401610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,17]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,8,17]]},"published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0527","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,12,1]]},"published":{"date-parts":[[2016,8,17]]}}}